Roundtable: The present and future of Cell & Gene Therapy, a perspective from innovators in the Québec ecosystem

Ensuring the precision, safety and cost effectiveness of cell and gene therapies are undoubtedly the biggest challenges faced by the industry to unlock the great potential of these cutting-edge evolving technologies.


Optimizing the manufacture and delivery of significant amounts of therapeutically potent cells, extend today’s frontiers in the field of cell therapy and regenerative medicine.


Choosing the right platforms, vectors, a comprehensive approach and the right partners will help you in the quest to deliver a better patient outcome avoiding possible complications.


Leaders in the pharma and biotech industry, health care sector and life science researchers will get insights about the latest advances in:

  • Regenerative medicine
  • Gene editing platforms
  • Tackling the critical limitations in developing CRISPR therapeutics
  • And the lessons learned during this journey

Dr. Francois-Thomas Michaud, PhD

Chief Executive Officer and Co-founder

Feldan Therapeutics

Dr. Michaud co-founded and became CEO of Feldan in 2007. Dr. Michaud and Feldan’s team worked on a research project that led to the development of the Feldan Shuttle, a peptide-based platform allowing efficient delivery in cells. Over the years, Dr. Michaud’s value-creating vision has shaped the business model of the company, which now focuses exclusively on the therapeutic development of shuttle-based applications.

Dr. Shant Der Sarkissian, PhD

Co-founder, President and CEO

Targa Biomedical inc.

Dr Der Sarkissian has 15 years of experience in cardiovascular research, drug development, gene and cell therapy. Co-founder of Targa a biotechnology company focused on developing treatments to increase the therapeutic impact of regenerative medicine and opportunities for organ transplantation. Professor at the Université de Montréal Department of Surgery. Ph.D. in Pharmacology, postdoctorate in Physiology and Functional Genomics. He is author / co-author of over 80 peer-reviewed publications including manuscripts, abstracts, book chapters and invention patents. Member of ThéCell research network.

Dr. Philip Roche, PhD

CEO

Jenthera Therapeutics

Bioengineer, inventor and technologist, with a passion for identifying and solving complex biomedical problems. Dr. Roche graduated from the University of Manchester in the U.K, in collaboration with AstraZeneca and obtained his Postdoctoral training at McGill University in Canada. He has over 15 years’ experience in leading highly innovative scientific research and producing commercially viable discoveries. Dr. Roche is a peer reviewed author in chemistry, microfabrication, photonics, molecular biology, bio-engineering, nanomedicine and gene editing and is the lead inventor on multiple patents.

NOW AVAILABLE ON DEMAND

Register now for this webinar

© 2021 Questex LLC, All right reserved.

685 Third Avenue, 21st Floor New York, NY 10017

Reproduction in whole or part is prohibited.